Enanta is a player in HCV, having licensed ABT-450, a protease inhibitor, to ABT (#msg-15492225) and EDP-239, an NS5A inhibitor, to NVS (#msg-72334186).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”